Such a ‘Goldilocks’ or ‘sweet‐spot’ protein dosage is not a new concept in broader signalling pathway research but is certainly the one that can account for the previous inconsistent findings for NDRG1 across different cancer types [43, 44, 45]. This evidence concerns the gene NDRG1 and cancer.